Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective
The continuing emergence of multi-drug resistant pathogens has sparked an interest in seeking alternative therapeutic options. Antimicrobial combinatorial therapy is one such avenue. A number of studies have been conducted, involving combinations of bacteriocins with other antimicrobials, to circumv...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-06-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmicb.2017.01205/full |
id |
doaj-575051311f8542849d222ca11329fd3f |
---|---|
record_format |
Article |
spelling |
doaj-575051311f8542849d222ca11329fd3f2020-11-24T23:37:45ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2017-06-01810.3389/fmicb.2017.01205281736Bacteriocin-Antimicrobial Synergy: A Medical and Food PerspectiveHarsh Mathur0Harsh Mathur1Des Field2Des Field3Mary C. Rea4Mary C. Rea5Paul D. Cotter6Paul D. Cotter7Colin Hill8Colin Hill9R. Paul Ross10R. Paul Ross11Teagasc Food Research Centre, MooreparkCork, IrelandAPC Microbiome Institute, University College CorkCork, IrelandAPC Microbiome Institute, University College CorkCork, IrelandSchool of Microbiology, University College CorkCork, IrelandTeagasc Food Research Centre, MooreparkCork, IrelandAPC Microbiome Institute, University College CorkCork, IrelandTeagasc Food Research Centre, MooreparkCork, IrelandAPC Microbiome Institute, University College CorkCork, IrelandAPC Microbiome Institute, University College CorkCork, IrelandSchool of Microbiology, University College CorkCork, IrelandAPC Microbiome Institute, University College CorkCork, IrelandSchool of Microbiology, University College CorkCork, IrelandThe continuing emergence of multi-drug resistant pathogens has sparked an interest in seeking alternative therapeutic options. Antimicrobial combinatorial therapy is one such avenue. A number of studies have been conducted, involving combinations of bacteriocins with other antimicrobials, to circumvent the development of antimicrobial resistance and/or increase antimicrobial potency. Such bacteriocin-antimicrobial combinations could have tremendous value, in terms of reducing the likelihood of resistance development due to the involvement of two distinct mechanisms of antimicrobial action. Furthermore, antimicrobial synergistic interactions may also have potential financial implications in terms of decreasing the costs of treatment by reducing the concentration of an expensive antimicrobial and utilizing it in combination with an inexpensive one. In addition, combinatorial therapies with bacteriocins can broaden antimicrobial spectra and/or result in a reduction in the concentration of an antibiotic required for effective treatments to the extent that potentially toxic or adverse side effects can be reduced or eliminated. Here, we review studies in which bacteriocins were found to be effective in combination with other antimicrobials, with a view to targeting clinical and/or food-borne pathogens. Furthermore, we discuss some of the bottlenecks which are currently hindering the development of bacteriocins as viable therapeutic options, as well as addressing the need to exercise caution when attempting to predict clinical outcomes of bacteriocin-antimicrobial combinations.http://journal.frontiersin.org/article/10.3389/fmicb.2017.01205/fullbacteriocinsantibiotic resistancesynergystressorspathogensantimicrobials |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Harsh Mathur Harsh Mathur Des Field Des Field Mary C. Rea Mary C. Rea Paul D. Cotter Paul D. Cotter Colin Hill Colin Hill R. Paul Ross R. Paul Ross |
spellingShingle |
Harsh Mathur Harsh Mathur Des Field Des Field Mary C. Rea Mary C. Rea Paul D. Cotter Paul D. Cotter Colin Hill Colin Hill R. Paul Ross R. Paul Ross Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective Frontiers in Microbiology bacteriocins antibiotic resistance synergy stressors pathogens antimicrobials |
author_facet |
Harsh Mathur Harsh Mathur Des Field Des Field Mary C. Rea Mary C. Rea Paul D. Cotter Paul D. Cotter Colin Hill Colin Hill R. Paul Ross R. Paul Ross |
author_sort |
Harsh Mathur |
title |
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective |
title_short |
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective |
title_full |
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective |
title_fullStr |
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective |
title_full_unstemmed |
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective |
title_sort |
bacteriocin-antimicrobial synergy: a medical and food perspective |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Microbiology |
issn |
1664-302X |
publishDate |
2017-06-01 |
description |
The continuing emergence of multi-drug resistant pathogens has sparked an interest in seeking alternative therapeutic options. Antimicrobial combinatorial therapy is one such avenue. A number of studies have been conducted, involving combinations of bacteriocins with other antimicrobials, to circumvent the development of antimicrobial resistance and/or increase antimicrobial potency. Such bacteriocin-antimicrobial combinations could have tremendous value, in terms of reducing the likelihood of resistance development due to the involvement of two distinct mechanisms of antimicrobial action. Furthermore, antimicrobial synergistic interactions may also have potential financial implications in terms of decreasing the costs of treatment by reducing the concentration of an expensive antimicrobial and utilizing it in combination with an inexpensive one. In addition, combinatorial therapies with bacteriocins can broaden antimicrobial spectra and/or result in a reduction in the concentration of an antibiotic required for effective treatments to the extent that potentially toxic or adverse side effects can be reduced or eliminated. Here, we review studies in which bacteriocins were found to be effective in combination with other antimicrobials, with a view to targeting clinical and/or food-borne pathogens. Furthermore, we discuss some of the bottlenecks which are currently hindering the development of bacteriocins as viable therapeutic options, as well as addressing the need to exercise caution when attempting to predict clinical outcomes of bacteriocin-antimicrobial combinations. |
topic |
bacteriocins antibiotic resistance synergy stressors pathogens antimicrobials |
url |
http://journal.frontiersin.org/article/10.3389/fmicb.2017.01205/full |
work_keys_str_mv |
AT harshmathur bacteriocinantimicrobialsynergyamedicalandfoodperspective AT harshmathur bacteriocinantimicrobialsynergyamedicalandfoodperspective AT desfield bacteriocinantimicrobialsynergyamedicalandfoodperspective AT desfield bacteriocinantimicrobialsynergyamedicalandfoodperspective AT marycrea bacteriocinantimicrobialsynergyamedicalandfoodperspective AT marycrea bacteriocinantimicrobialsynergyamedicalandfoodperspective AT pauldcotter bacteriocinantimicrobialsynergyamedicalandfoodperspective AT pauldcotter bacteriocinantimicrobialsynergyamedicalandfoodperspective AT colinhill bacteriocinantimicrobialsynergyamedicalandfoodperspective AT colinhill bacteriocinantimicrobialsynergyamedicalandfoodperspective AT rpaulross bacteriocinantimicrobialsynergyamedicalandfoodperspective AT rpaulross bacteriocinantimicrobialsynergyamedicalandfoodperspective |
_version_ |
1725519330084388864 |